Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 85Lymphoma, Follicular 53Lymphoma 50Lymphoma, Non-Hodgkin 47Lymphoma, Mantle-Cell 45Lymphoma, B-Cell, Marginal Zone 45Leukemia, Lymphocytic, Chronic, B-Cell 40Lymphoma, B-Cell 31Recurrence 20Burkitt Lymphoma 20Waldenstrom Macroglobulinemia 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasms 16Leukemia 11Leukemia, Hairy Cell 7Lymphoproliferative Disorders 5Hodgkin Disease 5Hematologic Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Dendritic Cell Sarcoma, Interdigitating 4Neoplasm, Residual 3Lymphoma, AIDS-Related 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Epstein-Barr Virus Infections 3beta-Thalassemia 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

Etoposide 3daratumumab 2Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2varlilumab 1prednylidene 1pomalidomide 1deltacortene 1carmustine, poliferprosan 20 drug combination 1belantamab mafodotin 1Specimen Handling 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Melphalan 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Dexamethasone 1Cytarabine 1Carmustine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmablastic Lymphoma × Rituximab × 1 year × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡